|
|
| Chaves,C.; Marque,C.R.; Trzesniak,C.; Machado de Sousa,J.P.; Zuardi,A.W.; Crippa,J.A.S.; Dursun,S.M.; Hallak,J.E.. |
| Growing consistent evidence indicates that hypofunction of N-methyl-D-aspartate (NMDA) transmission plays a pivotal role in the neuropathophysiology of schizophrenia. Hence, drugs which modulate NMDA neurotransmission are promising approaches to the treatment of schizophrenia. The aim of this article is to review clinical trials with novel compounds acting on the NMDA receptor (NMDA-R). This review also includes a discussion and translation of neuroscience into schizophrenia therapeutics. Although the precise mechanism of action of minocycline in the brain remains unclear, there is evidence that it blocks the neurotoxicity of NMDA antagonists and may exert a differential effect on NMDA signaling pathways. We, therefore, hypothesize that the effects of... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Schizophrenia; NMDA agonist; Glycine; Glutamate; Clinical trial; Minocycline. |
| Ano: 2009 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2009001100002 |
| |
